Latest news with #Holdings
Yahoo
6 hours ago
- Business
- Yahoo
Asian Penny Stocks With Market Caps At Least US$200M
As global markets navigate through volatility and trade tensions, Asian markets are under the spotlight for their resilience and growth potential. Penny stocks, a term that may seem outdated yet remains relevant, represent an intriguing investment area within these dynamic economies. By focusing on financial strength and long-term potential, this article explores several penny stocks in Asia that could offer surprising value to investors seeking opportunities in smaller or newer companies. Name Share Price Market Cap Financial Health Rating Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC) THB1.79 THB751.8M ★★★★★★ Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.425 SGD172.25M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.09 SGD8.23B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.50 HK$51.52B ★★★★★★ Lever Style (SEHK:1346) HK$1.19 HK$750.83M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.27 HK$2.12B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.95 HK$1.62B ★★★★★★ Click here to see the full list of 1,157 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Huanxi Media Group Limited is an investment holding company involved in the media and entertainment sectors in China and Hong Kong, with a market cap of HK$1.68 billion. Operations: The company generates revenue from its investment in film and TV programmes rights, amounting to HK$34.18 million. Market Cap: HK$1.68B Huanxi Media Group, operating in the media and entertainment sectors in China and Hong Kong, has a market cap of HK$1.68 billion but reported a significant drop in revenue to HK$34.18 million for 2024, compared to HK$1.33 billion the previous year. The company is unprofitable with a net loss of HK$260.82 million for 2024, attributed partly to delayed film releases expected to debut in 2025. Despite having more cash than debt and covering both short- and long-term liabilities with assets totaling HK$1.2 billion, it faces challenges with less than a year of cash runway if current free cash flow trends continue. Navigate through the intricacies of Huanxi Media Group with our comprehensive balance sheet health report here. Gain insights into Huanxi Media Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company involved in the research, development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in China, with a market cap of HK$8.69 billion. Operations: The company's revenue is derived from three main segments: Generic Medicine contributing CN¥1.10 billion, Medical Aesthetic Products generating CN¥744.22 million, and Innovative Medicine and Other Medicine adding CN¥109.67 million. Market Cap: HK$8.69B Sihuan Pharmaceutical Holdings Group, with a market cap of HK$8.69 billion, is navigating the challenges of unprofitability while leveraging its robust product pipeline in China's pharmaceutical and medical aesthetic sectors. Recent approvals for its PLLA and PCL fillers position it uniquely within the regenerative medical aesthetics market, potentially enhancing revenue streams as these products gain traction. Despite reporting a net loss of CN¥216.66 million for 2024, the company maintains strong short-term liquidity with assets exceeding liabilities and more cash than debt. The approval of Dapagliflozin Tablets further strengthens its diabetes treatment portfolio, offering potential growth avenues despite current financial setbacks. Click here to discover the nuances of Sihuan Pharmaceutical Holdings Group with our detailed analytical financial health report. Gain insights into Sihuan Pharmaceutical Holdings Group's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.42 billion. Operations: No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd. Market Cap: CN¥11.42B Tianjin Chase Sun Pharmaceutical, with a market cap of CN¥11.42 billion, is experiencing significant challenges in earnings growth, having reported negative earnings growth over the past year. Despite this, the company maintains strong liquidity with short-term assets of CN¥6.1 billion exceeding both short and long-term liabilities. The management team and board are considered experienced with average tenures of 2.1 and 3.2 years respectively. Recent dividend affirmations indicate some level of shareholder returns, although the dividend yield remains low at 0.79%. The company's debt is well covered by operating cash flow and interest payments by EBIT, reflecting solid financial health amidst volatility in profit margins. Take a closer look at Tianjin Chase Sun PharmaceuticalLtd's potential here in our financial health report. Review our growth performance report to gain insights into Tianjin Chase Sun PharmaceuticalLtd's future. Access the full spectrum of 1,157 Asian Penny Stocks by clicking on this link. Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1003 SEHK:460 and SZSE:300026. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
13 hours ago
- Business
- Yahoo
3 Promising Asian Penny Stocks With A Market Cap Below US$10B
Amidst the backdrop of global market volatility, with Asian markets navigating their own set of challenges and opportunities, investors are increasingly exploring diverse investment avenues. Penny stocks, though an older term in the investment lexicon, continue to capture interest due to their potential for significant growth at a relatively low cost. These stocks often represent smaller or emerging companies that can offer substantial value when supported by strong financial health and strategic growth plans. Name Share Price Market Cap Financial Health Rating Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC) THB1.79 THB751.8M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.425 SGD172.25M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.09 SGD8.23B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.50 HK$51.52B ★★★★★★ Lever Style (SEHK:1346) HK$1.19 HK$750.83M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.27 HK$2.12B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.95 HK$1.62B ★★★★★★ Click here to see the full list of 1,157 stocks from our Asian Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. focuses on the research, development, manufacture, and sale of bio-pharmaceutical products in China, with a market cap of approximately HK$7.48 billion. Operations: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has not reported specific revenue segments. Market Cap: HK$7.48B Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has shown recent sales growth, reporting CNY 179.91 million in the first quarter of 2025, up from CNY 147.65 million a year ago, though its net profit margins have decreased to 5.4% from last year's 12.6%. The company maintains strong short-term financial health with assets of CN¥1.6 billion exceeding liabilities significantly and has reduced its debt-to-equity ratio over five years to a minimal level of 0.2%. However, earnings have been volatile with negative growth trends and significant one-off gains impacting results, indicating potential risks for investors in this penny stock space. Get an in-depth perspective on Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's performance by reading our balance sheet health report here. Explore historical data to track Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Alibaba Health Information Technology Limited operates in pharmaceutical direct sales, a pharmaceutical e-commerce platform, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of HK$75.59 billion. Operations: The company's revenue from the distribution and development of pharmaceutical and healthcare products is CN¥30.60 billion. Market Cap: HK$75.59B Alibaba Health Information Technology Limited has demonstrated robust financial growth, with earnings increasing by 62.1% over the past year and revenue reaching CN¥30.60 billion. The company benefits from a strong balance sheet, with short-term assets of CN¥12.3 billion comfortably exceeding both short and long-term liabilities, while maintaining a debt-free status that alleviates concerns about interest coverage or cash flow constraints. Despite a large one-off loss impacting recent results, net profit margins have improved to 4.7%. However, the relatively inexperienced board could pose governance challenges for this rapidly growing entity in the penny stock market segment. Click to explore a detailed breakdown of our findings in Alibaba Health Information Technology's financial health report. Examine Alibaba Health Information Technology's earnings growth report to understand how analysts expect it to perform. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.63 billion, offers integrated solutions in design, construction, production, and services both within China and internationally. Operations: Shanghai Trendzone Holdings Group Co., Ltd has not reported any specific revenue segments. Market Cap: CN¥3.63B Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.63 billion, has shown some positive financial movements despite ongoing challenges. The company's debt to equity ratio has improved from 54% to 42.5% over five years, and short-term assets of CN¥1.3 billion exceed both short and long-term liabilities, indicating solid asset management. However, the company remains unprofitable with a net loss of CN¥19.16 million for Q1 2025 and volatile share prices persistently high compared to peers in China. Although revenue increased slightly year-over-year for Q1 2025, earnings have declined by 4% annually over the past five years. Click here to discover the nuances of Shanghai Trendzone Holdings GroupLtd with our detailed analytical financial health report. Understand Shanghai Trendzone Holdings GroupLtd's track record by examining our performance history report. Unlock more gems! Our Asian Penny Stocks screener has unearthed 1,154 more companies for you to here to unveil our expertly curated list of 1,157 Asian Penny Stocks. Want To Explore Some Alternatives? Rare earth metals are the new gold rush. Find out which 23 stocks are leading the charge. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1349 SEHK:241 and SHSE:603030. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Business
- Yahoo
Ausnutria Dairy Leads Our Selection Of 3 Asian Penny Stocks
Amidst global market volatility and economic uncertainties, Asian markets have been navigating through a landscape marked by trade tensions and fluctuating economic indicators. In such a climate, investors often look towards penny stocks as an avenue for potential growth opportunities. While the term 'penny stocks' may seem outdated, these smaller or newer companies can still offer significant value when they possess strong financial foundations. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.08 SGD8.19B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.53 HK$51.86B ★★★★★★ Lever Style (SEHK:1346) HK$1.17 HK$738.21M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.94 HK$1.62B ★★★★★★ Click here to see the full list of 1,167 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ausnutria Dairy Corporation Ltd is an investment holding company involved in the research, development, production, marketing, processing, packaging, and distribution of dairy and nutrition products with a market cap of HK$3.56 billion. Operations: The company's revenue is primarily derived from Dairy and Related Products, contributing CN¥7.10 billion, followed by Nutrition Products at CN¥304.56 million. Market Cap: HK$3.56B Ausnutria Dairy has shown a promising earnings growth of 35.3% over the past year, surpassing industry averages, although its five-year earnings trend reflects a decline. The company maintains strong short-term liquidity with CN¥4.4 billion in assets exceeding both short and long-term liabilities. Despite an increased debt-to-equity ratio of 37%, interest payments are well-covered by EBIT at 25.2 times coverage, though operating cash flow covers only 14% of debt, indicating potential cash flow constraints. Recent dividend increases highlight shareholder returns but raise concerns about sustainability due to limited free cash flow coverage. Jump into the full analysis health report here for a deeper understanding of Ausnutria Dairy. Learn about Ausnutria Dairy's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Hong Kong Robotics Group Holding Limited is an investment holding company that trades in electronic appliances across the People's Republic of China, Singapore, and Hong Kong, with a market cap of HK$3.28 billion. Operations: The company's revenue is primarily derived from building construction contracting (HK$72.40 million), centralised heating (HK$50.07 million), geothermal energy (HK$16.87 million), customised technical support (HK$14.87 million), property investment (HK$6.32 million), and money lending (HK$6.98 million). Market Cap: HK$3.28B Hong Kong Robotics Group Holding Limited, with a market cap of HK$3.28 billion, remains unprofitable despite diverse revenue streams from building construction contracting and centralised heating. The company's short-term assets of HK$1.0 billion comfortably cover both short and long-term liabilities, reflecting solid liquidity management. While the company has a satisfactory net debt to equity ratio of 32.8%, the increased debt levels over five years warrant caution. Recent developments include a name change and collaboration on a healthcare project in Jiangsu Province, which could enhance its strategic positioning but also introduces execution risks amidst ongoing volatility in its share price. Click to explore a detailed breakdown of our findings in Hong Kong Robotics Group Holding's financial health report. Gain insights into Hong Kong Robotics Group Holding's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: China Oriental Group Company Limited manufactures and sells iron and steel products for downstream steel manufacturers in the People's Republic of China, with a market cap of HK$4.91 billion. Operations: The company generates revenue primarily from its Iron and Steel segment, which accounts for CN¥42.86 billion, alongside a smaller contribution of CN¥96.83 million from Real Estate activities. Market Cap: HK$4.91B China Oriental Group, with a market cap of HK$4.91 billion, recently reported a turnaround from a CN¥159.69 million net loss to a CN¥149.11 million net profit for 2024, aided by improved earnings and stable revenue of CN¥42.96 billion primarily from its iron and steel segment. The company announced dividends totaling HKD 0.06 per share for the year ended December 2024, reflecting shareholder returns despite an unstable dividend history. While the management team is experienced and interest coverage is adequate, concerns remain over increased debt levels and low return on equity at 0.9%. Take a closer look at China Oriental Group's potential here in our financial health report. Assess China Oriental Group's previous results with our detailed historical performance reports. Take a closer look at our Asian Penny Stocks list of 1,167 companies by clicking here. Contemplating Other Strategies? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1717 SEHK:370 and SEHK:581. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Asian Penny Stocks To Consider In May 2025
As global markets face volatility and economic uncertainties, the Asian stock market continues to capture attention with its unique dynamics and opportunities. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite being considered somewhat outdated. By focusing on those with robust financials and growth potential, investors can uncover hidden gems that offer stability alongside promising prospects for growth. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.08 SGD8.19B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.53 HK$51.86B ★★★★★★ Lever Style (SEHK:1346) HK$1.17 HK$738.21M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.94 HK$1.62B ★★★★★★ Click here to see the full list of 1,167 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: EROAD Limited offers electronic on-board units and software as a service to the transport industry across New Zealand, the United States, and Australia, with a market cap of NZ$252.48 million. Operations: The company has not reported specific revenue segments. Market Cap: NZ$252.48M EROAD Limited, with a market cap of NZ$252.48 million, has shown promising financial performance by achieving profitability recently and reporting sales of NZ$194.4 million for the fiscal year ended March 31, 2025. The company's net income was NZ$1.4 million compared to a net loss the previous year, indicating improved margins. EROAD's debt management is commendable with a reduced debt to equity ratio from 69.8% to 8% over five years and satisfactory net debt levels at 3.8%. However, challenges remain with high share price volatility and an inexperienced board and management team impacting stability perceptions in the penny stock landscape. Unlock comprehensive insights into our analysis of EROAD stock in this financial health report. Review our growth performance report to gain insights into EROAD's future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: China Ding Yi Feng Holdings Limited is a publicly owned investment manager with a market cap of HK$569.92 million. Operations: The company's revenue segment is Investment Holding, which reported a revenue of -HK$245.20 million. Market Cap: HK$569.92M Ding Yi Feng Holdings Group International, with a market cap of HK$569.92 million, is pre-revenue and reported substantial negative revenue of -HK$367.55 million for 2024. Despite its unprofitable status and high volatility compared to other Hong Kong stocks, the company maintains a debt-free position with short-term assets exceeding liabilities significantly. The seasoned board has an average tenure of 8.8 years, which may provide stability amid recent changes like auditor transitions announced in May 2025. While the stock's price remains volatile, sufficient cash reserves suggest operational continuity for over a year without additional funding needs. Click here and access our complete financial health analysis report to understand the dynamics of Ding Yi Feng Holdings Group International. Gain insights into Ding Yi Feng Holdings Group International's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Boustead Singapore Limited is an investment holding company that offers energy engineering, real estate, geospatial, and healthcare technology solutions across various regions worldwide with a market capitalization of SGD560.45 million. Operations: No specific revenue segments are reported for this company. Market Cap: SGD560.45M Boustead Singapore Limited, with a market cap of SGD560.45 million, recently reported full-year sales of SGD527.1 million and net income growth to SGD95.05 million, reflecting improved profit margins from 8.4% to 18%. The company shows financial robustness with cash exceeding total debt and high operating cash flow coverage of debt at 970.2%. Earnings have grown significantly by 48.1% over the past year, surpassing both its five-year average and industry growth rates. While trading below estimated fair value by 44.5%, the stock's dividend track record remains unstable despite strong short-term asset coverage over liabilities. Click here to discover the nuances of Boustead Singapore with our detailed analytical financial health report. Learn about Boustead Singapore's historical performance here. Explore the 1,167 names from our Asian Penny Stocks screener here. Want To Explore Some Alternatives? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NZSE:ERD SEHK:612 and SGX:F9D. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 days ago
- Business
- Yahoo
Asian Penny Stocks Under US$800M Market Cap To Consider
As global markets face volatility amid renewed tariff threats and economic uncertainties, investors are increasingly looking for opportunities in diverse regions, including Asia. Penny stocks, often representing smaller or newer companies, continue to intrigue investors with their potential for value and growth despite the term's somewhat outdated connotation. This article will explore several Asian penny stocks that stand out due to their financial resilience and potential long-term promise. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.07 SGD8.15B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.49 HK$51.41B ★★★★★★ Lever Style (SEHK:1346) HK$1.14 HK$719.28M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.21 HK$2.02B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.98 HK$1.65B ★★★★★★ Click here to see the full list of 1,169 stocks from our Asian Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Beyond Securities Public Company Limited operates in the securities business in Thailand with a market capitalization of approximately THB2.50 billion. Operations: No revenue segments have been reported for Beyond Securities. Market Cap: THB2.5B Beyond Securities, operating in Thailand's securities sector, reported a significant increase in revenue to THB 292.35 million for Q1 2025, up from THB 209.73 million the previous year. Despite this growth, the company remains unprofitable with a net loss of THB 240.92 million for the same period. Beyond Securities has more cash than total debt and maintains a stable cash runway exceeding three years due to positive free cash flow levels. However, its share price has been highly volatile recently and it continues to face challenges with negative return on equity and increasing losses over five years. Navigate through the intricacies of Beyond Securities with our comprehensive balance sheet health report here. Understand Beyond Securities' track record by examining our performance history report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Geo Energy Resources Limited is an investment holding company involved in the mining, production, and trading of coal, with a market cap of SGD530.33 million. Operations: Geo Energy Resources Limited has not reported any specific revenue segments. Market Cap: SGD530.33M Geo Energy Resources Limited, with a market cap of SGD530.33 million, reported Q1 2025 sales of US$166.41 million and net income of US$14.13 million, indicating growth from the previous year. Despite this, the company faces challenges such as low return on equity at 7.7% and interest coverage issues with EBIT only covering interest payments twice over. While its short-term assets exceed liabilities significantly, long-term liabilities remain uncovered by current assets. The board's lack of experience contrasts with a seasoned management team averaging 3.7 years tenure, and the stock has experienced high volatility recently despite being valued attractively compared to peers. Take a closer look at Geo Energy Resources' potential here in our financial health report. Assess Geo Energy Resources' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Shenzhen Jinjia Group Co., Ltd. focuses on the research, development, and production of packaging materials in China, with a market cap of CN¥5.43 billion. Operations: The company generates revenue of CN¥2.70 billion from its operations within China. Market Cap: CN¥5.43B Shenzhen Jinjia Group Co., Ltd. has a market cap of CN¥5.43 billion and reported first-quarter 2025 sales of CN¥635.29 million, down from CN¥794.19 million the previous year, with net income dropping to CN¥66.62 million from CN¥120.61 million. Despite having more cash than debt and stable short-term asset coverage for liabilities, the company faces challenges such as declining earnings growth and profit margins affected by a significant one-off loss of CN¥184 million in the past year. The board is experienced with an average tenure of 9.7 years, but management experience data is insufficient for assessment. Click to explore a detailed breakdown of our findings in Shenzhen Jinjia GroupLtd's financial health report. Learn about Shenzhen Jinjia GroupLtd's future growth trajectory here. Dive into all 1,169 of the Asian Penny Stocks we have identified here. Ready To Venture Into Other Investment Styles? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SET:BYD SGX:RE4 and SZSE:002191. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
